Santen Pharmaceutical Co Ltd

Common Name
Santen Pharmaceutical
Country
Japan
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
3,849
Ticker
4536
Exchange
TOKYO STOCK EXCHANGE
Description
Santen Pharmaceutical Co., Ltd. is a prominent pharmaceutical company focusing on ophthalmology. Established in 1890 and headquartered in Osaka, Japan, Santen specializes in the research, development,...

Santen Pharmaceutical's GHG Emissions Data Preview

In 2024, Santen Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Santen Pharmaceutical has also provided a category-level breakdown for 8 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 2
Market-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Location-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
0000000
Download Data

Verified Sources Behind Santen Pharmaceutical’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Santen Pharmaceutical’s data sources below and access millions more through our Disclosure Search.

a. Santen Pharmaceutical's ESG Data Spreadsheet 2025
a. Santen Pharmaceutical's ESG Data Spreadsheet 2025
b. Santen Pharmaceutical's ESG Data Spreadsheet 2023
b. Santen Pharmaceutical's ESG Data Spreadsheet 2023

Insights into Santen Pharmaceutical's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Santen Pharmaceutical amounted to 52,946 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Santen Pharmaceutical increased by 33.66%, suggesting that the company faced challenges in reducing its emissions from its core operations. a

Santen Pharmaceutical's Scope 1 Emissions Over Time

201820192020202120222023202404.5 k9 k13.5 k18 ktCO2e+2%-15%0%+14%0%+2%
  • Total Scope 1
  • Year-over-Year Change

What are Santen Pharmaceutical's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Santen Pharmaceutical were 17,372 metric tons of CO₂ equivalent (tCO₂e). a

Has Santen Pharmaceutical reduced its Scope 1 emissions over time?

Since 2018, Santen Pharmaceutical's Scope 1 emissions have increased by 2.08%, reflecting a rising long-term trend in Scope 1 emissions over time. a b

Compared to the previous year (2023), Santen Pharmaceutical's Scope 1 emissions increased by 2.06%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a

What are Santen Pharmaceutical's Scope 2 emissions?

In 2024, Santen Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 17,498 tCO₂e using the market-based method and 35,574 tCO₂e using the location-based method. a

Has Santen Pharmaceutical reduced its Scope 2 emissions over time?

Since 2018, Santen Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions ( Location-Based) have increased by 107.53%, reflecting a rising long-term trend in Scope 2 emissions over time. a b

Compared to the previous year (2023), Santen Pharmaceutical's Scope 2 emissions (Location-Based) rose by 57.47% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy a

What methodology does Santen Pharmaceutical use for Scope 2 reporting?

In 2024, Santen Pharmaceutical reported its Scope 2 emissions using the market-based method and using the location-based method. a

Santen Pharmaceutical's Scope 2 Emissions Over Time

201820192020202120222023202409 k18 k27 k36 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Santen Pharmaceutical's Value Chain Emissions

In 2024, Santen Pharmaceutical reported 154,563 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a

The 2024 disclosure of Santen Pharmaceutical includes a breakdown across 8 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year. a

Santen Pharmaceutical's Scope 3 Emissions Over Time

2018201920202021202220232024050 k100 k150 k200 ktCO2e-17%+16%-18%+8%+47%-21%
  • Total Scope 3
  • Year-over-Year Change

What are Santen Pharmaceutical's Scope 3 emissions?

In 2024, Santen Pharmaceutical reported total Scope 3 emissions of 154,563 metric tons of CO₂ equivalent (tCO₂e). a

Approximately 99.77% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.23% came from downstream activities like product use, distribution, and end-of-life treatment. a

Has Santen Pharmaceutical reduced its Scope 3 emissions over time?

Since 2018, Santen Pharmaceutical's Scope 3 emissions have remained relatively stable, indicating that Santen Pharmaceutical 's emissions have plateaued with no significant change in its value chain footprint. a b

Compared to the previous year (2023), Santen Pharmaceutical's Scope 3 emissions decreased by 21.37%, highlighting the company's efforts to lower indirect emissions from its value chain. a

What categories of Scope 3 emissions does Santen Pharmaceutical disclose?

In 2024, Santen Pharmaceutical reported emissions for 8 out of the 15 Scope 3 categories defined by the GHG Protocol. a

This partial disclosure allows for some insight into the company's indirect impacts.

What are the main sources of Santen Pharmaceutical's Scope 3 emissions?

In 2024, the largest contributors to Santen Pharmaceutical's Scope 3 emissions were: a

  • Purchased Goods and Services (Cat. 1): 95,560 tCO₂e (61.83%)
  • Capital Goods (Cat. 2): 49,452 tCO₂e (31.99%)
  • Fuel- and Energy-Related Services (Cat. 3): 5,257 tCO₂e (3.4%)

Santen Pharmaceutical's Scope 3 Emissions by Categories

Fuel- andEnergy-RelatedServices (Cat. 3)(3.4%)Capital Goods(Cat. 2)(32.0%)Purchased Goods andServices (Cat. 1)(61.8%)

Insights into Santen Pharmaceutical’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Santen Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 17,372 tCO₂e and total revenues of USD 1,994 millions. This translates into an emissions intensity of 8.71 tCO₂e per millions USD. a

Santen Pharmaceutical's Scope 1 Emissions Intensity Compared to Peers

501,00020,000200,0005,000,000Scope 1 Emissions (tCO2e)505002,00010,00050,000Revenues (Millions of USD)SNMeniconYear: 2023Scope 1: 3,930 tCO2eRevenue: $M 827Scope 1 Intensity: 4.75 tCO2e/$MAs OneYear: 2024Scope 1: 165 tCO2eRevenue: $M 631Scope 1 Intensity: 0.26 tCO2e/$MHisamitsu PharmaceuticalYear: 2022Scope 1: 7,862 tCO2eRevenue: $M 1,040Scope 1 Intensity: 7.56 tCO2e/$MSawai Group HoldingsYear: 2023Scope 1: 19,500 tCO2eRevenue: $M 1,229Scope 1 Intensity: 15.87 tCO2e/$MNihon KohdenYear: 2023Scope 1: 4,250 tCO2eRevenue: $M 1,551Scope 1 Intensity: 2.74 tCO2e/$MJCR PharmaceuticalsYear: 2022Scope 1: 3,315 tCO2eRevenue: $M 419Scope 1 Intensity: 7.92 tCO2e/$MPeptiDreamYear: 2023Scope 1: 3,156 tCO2eRevenue: $M 203Scope 1 Intensity: 15.55 tCO2e/$MSundrugYear: 2024Scope 1: 22,197 tCO2eRevenue: $M 4,964Scope 1 Intensity: 4.47 tCO2e/$MH.U. Group HoldingsYear: 2022Scope 1: 13,418 tCO2eRevenue: $M 2,237Scope 1 Intensity: 6.00 tCO2e/$MSysmexYear: 2024Scope 1: 13,449 tCO2eRevenue: $M 3,047Scope 1 Intensity: 4.41 tCO2e/$MSSSugi HoldingsYear: 2023Scope 1: 1,531 tCO2eRevenue: $M 4,898Scope 1 Intensity: 0.31 tCO2e/$MOno PharmaceuticalYear: 2024Scope 1: 8,100 tCO2eRevenue: $M 3,319Scope 1 Intensity: 2.44 tCO2e/$MMatsukiyoCocokara & CoYear: 2023Scope 1: 1,764 tCO2eRevenue: $M 7,142Scope 1 Intensity: 0.25 tCO2e/$MChugai PharmaceuticalYear: 2024Scope 1: 51,143 tCO2eRevenue: $M 7,456Scope 1 Intensity: 6.86 tCO2e/$MSuzukenYear: 2023Scope 1: 26,491 tCO2eRevenue: $M 17,378Scope 1 Intensity: 1.52 tCO2e/$MTsuruha HoldingsYear: 2023Scope 1: 3,424 tCO2eRevenue: $M 6,940Scope 1 Intensity: 0.49 tCO2e/$MOtsuka HoldingsYear: 2021Scope 1: 1,030,000 tCO2eRevenue: $M 13,021Scope 1 Intensity: 79.10 tCO2e/$MSMSYear: 2023Scope 1: 220 tCO2eRevenue: $M 343Scope 1 Intensity: 0.64 tCO2e/$MAstellas PharmaYear: 2023Scope 1: 59,203 tCO2eRevenue: $M 11,401Scope 1 Intensity: 5.19 tCO2e/$MTsumura & CoYear: 2021Scope 1: 39,385 tCO2eRevenue: $M 1,055Scope 1 Intensity: 37.32 tCO2e/$MDaiichi SankyoYear: 2024Scope 1: 91,836 tCO2eRevenue: $M 10,576Scope 1 Intensity: 8.68 tCO2e/$MNNNippon ShinyakuYear: 2023Scope 1: 4,366 tCO2eRevenue: $M 1,082Scope 1 Intensity: 4.03 tCO2e/$MKyowa KirinYear: 2024Scope 1: 16,133 tCO2eRevenue: $M 3,157Scope 1 Intensity: 5.11 tCO2e/$MSumitomo PharmaYear: 2023Scope 1: 27,093 tCO2eRevenue: $M 4,171Scope 1 Intensity: 6.50 tCO2e/$MSanten PharmaceuticalYear: 2024Scope 1: 17,372 tCO2eRevenue: $M 1,994Scope 1 Intensity: 8.71 tCO2e/$M

How does Santen Pharmaceutical's GHG emissions intensity compare to its peers?

In 2024, Santen Pharmaceutical reported a Scope 1 emissions intensity of 8.71 tCO₂e per millions USD. Compared to the peer group median of 4.93 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a

Where does Santen Pharmaceutical rank on GHG emissions intensity within its industry?

In 2024, Santen Pharmaceutical ranked 21 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a

This places Santen Pharmaceutical among the least efficient performers, with one of the highest emissions intensities in its sector. a

Insights into Santen Pharmaceutical's Total Carbon Footprint

In 2024, Santen Pharmaceutical reported a total carbon footprint of 207,509 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 12.14% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output. a

The largest contributor to Santen Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 74.48% of the company's total carbon footprint, followed by Scope 2 emissions at 17.14%. a

Want Full Access to Santen Pharmaceutical's GHG Emissions Dataset?
Sign Up